KDR and neoplasm: To counteract the activation of pathological pathways in various neoplastic diseases, a range of VEGF and VEGF receptor (VEGFR) inhibitors have been created, such as sorafenib, sunitinib, vandetanib, lenvatinib, axitinib, bevacizumab, ramucirumab, cabozantinib, and pazopanib [118].